United States Orphan Drug Designation For Treatment Of Soft Tissue Sarcomas Granted To Spear T-Cells Targeting Mage-A4
Adaptimmune Therapeutics Plc, A Leader In T-Cell Therapy To Treat Cancer, Today Announced That The United States Food And Drug Administration (Fda) Has Granted Orphan Drug Designation (Odd) To Spear T-Cells Targeting Mage-A4 (Adaptimmune’S Adp-A2M4 Program) For The Treatment Of Soft Tissue Sarcomas. Orphan Designation By Fda Was Created To Encourage The Development Of Drugs For Rare Diseases, Such As Sarcomas.
Let’s apply Data-Driven Pricing to Your APIs
Sick and tired of always wondering if you are being asked to pay the right price for your APIs? This empowers you with the answers you need to make the right decisions in the Global API market.
Chemxpert Database is one of the biggest and most comprehensive directories of pharma and chemicals, manufacturers, suppliers and information. Provided with current information on prices, demand and transactions, it gives you instant feedback on whether you are buying what is right and at the right time.
Start using market intelligence today and allow yourself to be in control in the API market.
Check it out today and make more informed sourcing decisions!
Learn More!